Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 65

Results For "2023"

1090 News Found

Narayana Hrudayalaya posts Q1 FY24 consolidated PAT at Rs. 183.95 Cr
News | August 03, 2023

Narayana Hrudayalaya posts Q1 FY24 consolidated PAT at Rs. 183.95 Cr

The company has reported total income of Rs. 1248.51 crores during the period ended June 30, 2023


Medica, Kolkata and UNICEF collaborate to empower working mothers
News | August 03, 2023

Medica, Kolkata and UNICEF collaborate to empower working mothers

Medica Superspecialty Hospital becomes the first private hospital in Eastern India to collaborate with UNICEF for breastfeeding workshop


Zydus receives USFDA's final approval for Indomethacin Suppository with competitive generic therapy designation
Drug Approval | August 03, 2023

Zydus receives USFDA's final approval for Indomethacin Suppository with competitive generic therapy designation

Zydus' Indomethacin suppositories also been granted 180-day CGT exclusivity to market this product.


Roquette to acquire Qualicaps from Mitsubishi Chemical Group
News | August 03, 2023

Roquette to acquire Qualicaps from Mitsubishi Chemical Group

Qualicaps is the third largest producer of hard capsules for oral dosage solutions


Thyrocare Technologies posts Q1 FY24 PAT at Rs. 17.30 Cr
News | August 02, 2023

Thyrocare Technologies posts Q1 FY24 PAT at Rs. 17.30 Cr

The company has reported total income of Rs. 135.87 crores during the period ended June 30, 2023


Bliss GVS Pharma Q1 FY2024 consolidated PAT up at Rs. 14.68 Cr
News | August 02, 2023

Bliss GVS Pharma Q1 FY2024 consolidated PAT up at Rs. 14.68 Cr

The company has reported total income of Rs. 164.63 crores during the period ended June 30, 2023


Lupin receives approval from US FDA for Turqoz
Drug Approval | August 02, 2023

Lupin receives approval from US FDA for Turqoz

Norgestrel and Ethinyl Estradiol Tablets USP (RLD Lo/Ovral-28) had an estimated annual sale of USD 34 million in the U.S. (IQVIA MAT Mar 2023)


Jemperli plus chemotherapy approved in the US as the first new frontline treatment option for dMMR/MSI-H primary advanced or recurrent endometrial cancer
Drug Approval | August 01, 2023

Jemperli plus chemotherapy approved in the US as the first new frontline treatment option for dMMR/MSI-H primary advanced or recurrent endometrial cancer

Jemperli is the only immuno-oncology treatment approved in the frontline setting for this patient population in combination with chemotherapy


Biogen to acquire Reata Pharmaceuticals
News | July 31, 2023

Biogen to acquire Reata Pharmaceuticals

Proposed acquisition represents meaningful step forward in Biogen’s strategy for sustainable growth


New products and nutraceuticals added under Jan Aushadhi Pariyojana
Policy | July 31, 2023

New products and nutraceuticals added under Jan Aushadhi Pariyojana

The product basket increased to 1800 medicines and 285 Surgical Equipment